Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune restoration with abatacept in CVID and related disorders
2022-004155-13Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Jan 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in common variable immunodeficiency (CVID), interstitial lung disease (ILD) and Granulomatous disease associated with common variable immunodeficiency (GLILD), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Early predictive markers of immune restoration under abatacept. Started Jan 2023; status: completed.
02
Drugs
abatacept
03
Conditions
common variable immunodeficiency (CVID)interstitial lung disease (ILD)Granulomatous disease associated with common variable immunodeficiency (GLILD)
Beyond the preview
Go deeper on 2022-004155-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004155-13.